Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1192171-69-9
2. Vonafexor [inn]
3. Eyp001
4. Xg6dg6a1un
5. Vonafexor(plx007,eyp-001)
6. 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic Acid
7. 2-benzofurancarboxylic Acid, 4-chloro-5-(4-((2,6-dichlorophenyl)sulfonyl)-1-piperazinyl)-
8. 4-chloro-5-(4-((2,6-dichlorophenyl)sulfonyl)piperazin-1-yl)benzofuran-2-carboxylic Acid
9. 2156704-25-3
10. Pxl007
11. Unii-xg6dg6a1un
12. Eyp-001
13. Vonafexor [who-dd]
14. Plx007
15. Schembl1893285
16. Bcp33693
17. Ex-a4037
18. Akos040759412
19. Eyp001;eyp 001;eyp-001
20. Ac-36482
21. Ms-29108
22. Hy-109197
23. Cs-0119143
24. F94108
| Molecular Weight | 489.8 g/mol |
|---|---|
| Molecular Formula | C19H15Cl3N2O5S |
| XLogP3 | 4.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 99.4 |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 733 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
The proceeds will fund the ongoing ALPESTRIA-1 study evaluating EYP001 (vonafexor), a highly selective and oral FXR agonist, in patients with Alport syndrome.
Lead Product(s): Vonafexor,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Vesalius Biocapital
Deal Size: $36.8 million Upfront Cash: Undisclosed
Deal Type: Series C Financing June 12, 2025
Lead Product(s) : Vonafexor,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Vesalius Biocapital
Deal Size : $36.8 million
Deal Type : Series C Financing
ENYO Completes Series C to Advance Phase 2 Study in Alport Syndrome
Details : The proceeds will fund the ongoing ALPESTRIA-1 study evaluating EYP001 (vonafexor), a highly selective and oral FXR agonist, in patients with Alport syndrome.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 12, 2025
Details:
Undisclosed
Lead Product(s): Vonafexor,Inapplicable
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 23, 2025
Lead Product(s) : Vonafexor,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2025
Details:
Undisclosed
Lead Product(s): Vonafexor,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 22, 2024
Lead Product(s) : Vonafexor,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2024
Details:
Financing will support the Phase 2 Alpestria-1 study and profiling of EYP001 (vonafexor), a selective NR1H4 agonist, in Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Lead Product(s): Vonafexor,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: OrbiMed Advisors
Deal Size: $42.5 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 01, 2024
Lead Product(s) : Vonafexor,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : OrbiMed Advisors
Deal Size : $42.5 million
Deal Type : Series C Financing
ENYO Pharma Secures €39M in Series C and FDA Clearance for Vonafexor
Details : Financing will support the Phase 2 Alpestria-1 study and profiling of EYP001 (vonafexor), a selective NR1H4 agonist, in Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 01, 2024
Details:
Undisclosed
Lead Product(s): Vonafexor,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 22, 2019
Lead Product(s) : Vonafexor,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2019
Details:
Undisclosed
Lead Product(s): Vonafexor,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: CPR Pharma Services
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 19, 2018
Lead Product(s) : Vonafexor,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : CPR Pharma Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug Drug Interaction Study for EYP001 With Entecavir
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2018
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
38
PharmaCompass offers a list of Vonafexor API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vonafexor manufacturer or Vonafexor supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vonafexor manufacturer or Vonafexor supplier.
PharmaCompass also assists you with knowing the Vonafexor API Price utilized in the formulation of products. Vonafexor API Price is not always fixed or binding as the Vonafexor Price is obtained through a variety of data sources. The Vonafexor Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Vonafexor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vonafexor, including repackagers and relabelers. The FDA regulates Vonafexor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vonafexor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Vonafexor supplier is an individual or a company that provides Vonafexor active pharmaceutical ingredient (API) or Vonafexor finished formulations upon request. The Vonafexor suppliers may include Vonafexor API manufacturers, exporters, distributors and traders.
Vonafexor Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vonafexor GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vonafexor GMP manufacturer or Vonafexor GMP API supplier for your needs.
A Vonafexor CoA (Certificate of Analysis) is a formal document that attests to Vonafexor's compliance with Vonafexor specifications and serves as a tool for batch-level quality control.
Vonafexor CoA mostly includes findings from lab analyses of a specific batch. For each Vonafexor CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vonafexor may be tested according to a variety of international standards, such as European Pharmacopoeia (Vonafexor EP), Vonafexor JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vonafexor USP).
